Tirzepatide, a dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic ... with mean fasting insulin percent reductions of 27.76% (P =.003; 10 mg dose) and 37.0% (P ...

Participants who tolerated 10 mg but did not tolerate 15 mg continued on 10 ... and GLP-1 (glucagon-like peptide-1) obesity medication. Tirzepatide tackles an underlying cause of excess weight. It ...

Official data shows that since 2019, this medication has been linked to 23 deaths and 1,179 serious adverse reactions in the ...

Weight loss jabs are now are now available on the NHS for those with a prescription. But a black market for the in-demand ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

The observational study, led by Washington University clinical epidemiologist Dr Ziyad Al-Aly, analysed glucagon-like peptide 1 receptor ... also known as tirzepatide and made by Eli Lilly ...

One of the most promising developments in obesity management is the introduction of medications like tirzepatide and semaglutide, both of which are glucagon-like peptide-1 (GLP-1) receptor agonists.

The N-terminal pro–B-type natriuretic peptide (NT-proBNP ... as compared with placebo — empagliflozin at a dose of 10 mg daily in the EMPEROR-Preserved trial (hazard ratio, 0.79; 95% CI ...